<DOC>
	<DOCNO>NCT03058198</DOCNO>
	<brief_summary>The epidermal growth factor receptor variant Ⅲ ( EGFR vⅢ ) commonly detect high-grade glioma , also important epitope EGFR-targeted therapy correlate poor prognosis . However , detection mutant usually need resected tumor sample . For biopsy sample , test result may represent EGFR vⅢ status whole tumor tissue heterogeneity tumor . It also applicable patient suitable surgical procedure due tumor location patient ' general condition . Because importance epidermal growth factor receptor ( EGFR ) signal pathway oncogenesis , maintenance , progression high grade glioma , intense effort develop noninvasive molecular image approach selection monitor EGFR-targeted therapy . Based investigator ' previous study , investigator plan perform PET scan participant high grade glioma injection second generation EGFR tracer ,89Zr-ABT806 , specifically bind EGFR vⅢ . After fuse PET MRI image , investigator precisely obtain tissue '' hot-spot '' PET image multimodal-neuronavigation-guided tumor biopsy . EGFRvⅢ status detect molecular method analyze correlation 89Zr-ABT806 PET image qualitatively quantitatively . Investigators ' final goal detect EGFR vⅢ noninvasive molecular imaging procedure clinical outcome prediction selection EGFR-targeted therapy .</brief_summary>
	<brief_title>The Research 89Zr-ABT806 PET Imaging High Grade Glioma</brief_title>
	<detailed_description />
	<mesh_term>Glioma</mesh_term>
	<criteria>1 . Clinical manifestation image examination ( CT , MRI , et al ) accordance high grade glioma 2 . No PET/CT scan contraindication 3 . No MRI scan contraindication 4 . Patients older 18 year old 5 . ECOG score 0 2 6 . Patients sufficient bone marrow , kidney liver function reserve . 7 . All patient give write informed consent . 1 . Patient receive immune therapy , radiation therapy , chemotherapy , hormone drug , biological product clinical trial within 14 day . 2 . Patient receive EGFR monoclonal antibody therapy within 4 week . 3 . Patients fully recover form past drug toxicity reaction ( CTCAE grade 2 ) . 4 . Patient receive major surgery within 7 day . 5 . Patients allergies immunoglobulin . 6 . Breastfeeding woman . 7. pregnant woman 8 . Patients severe clinical condition . 9 . Inability give inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Glioma</keyword>
	<keyword>PET</keyword>
	<keyword>EGFR vIII</keyword>
	<keyword>Multimodal neuronavigation</keyword>
	<keyword>Molecular pathology</keyword>
	<keyword>PET-CT</keyword>
	<keyword>Neuronavigation</keyword>
</DOC>